Spirovant Sciences, a gene therapy company developing treatments for respiratory diseases, including cystic fibrosis (CF), announced today the launch ...
PHILADELPHIA, Nov. 4, 2021 /PRNewswire/ -- Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today presented SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021). In oral and poster presentations, Spirovant summarized recent pre-clinical data suggesting SP-101 functionally corrects human CF airway epithelia. In addition, the presentations showed that CFTR expression and CF correction exhibited by SP-101 are dose responsive and durable, demonstrating that SP-101 is a promising drug development candidate. SP-101 is intended for inhalation in patients with CF who do not benefit from or have only minimal benefit from treatment with small molecule CFTR modulators, which is approximately 20% of all patients with CF. A copy of the presentation slides and poster are available on the Spirovant website.